IRX-2
AssetAlso immunotherapy, allogeneic prostate vaccine
Allogeneic whole-cell prostate cancer vaccine expressing GM-CSF to stimulate anti-tumor immune response
- Stage
- Phase 3
- Modality
- Vaccine
- Target
- Inflammation
- 2
- Indications
- 121
- Trials
- 2
- Developers
Indications
2Prostate cancer
Phase 3, Terminated, NCT00089856, clinicaltrials.gov, 7 Oct 2026
Squamous cell carcinoma of the oral cavity
Phase 2, Completed, NCT02609386, clinicaltrials.gov, 7 Oct 2026
In the full profile
- Targets and what it contains2
- Owner and partners2
- Trials121
- Evidence for its targets2
- Competitors3
- Signals9
Every asset’s record: target, stage, trials and the evidence behind it.